<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124529">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095873</url>
  </required_header>
  <id_info>
    <org_study_id>PJT_HATFF</org_study_id>
    <secondary_id>TSB101129</secondary_id>
    <nct_id>NCT02095873</nct_id>
  </id_info>
  <brief_title>Healthy Aging Through Functional Food</brief_title>
  <acronym>HATFF</acronym>
  <official_title>Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technology Strategy Board (UK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unilever R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Warwick</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: Research Councils UK</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether dietary inducers of glyoxalase 1 are
      effective in improving metabolic and vascular health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate dietary inducers of glyoxalase 1 for effects on
      metabolic and vascular health in overweight volunteers at risk of developing type 2
      diabetes. The research objectives are:

      (i) To evaluate dietary inducers of glyoxalase 1 for effects on markers of glucose
      metabolism during an oral glucose tolerance test (oGTT), (ii) To evaluate dietary inducers
      of glyoxalase 1 for effects on vascular function on three levels, using finger fold
      capillary density by capillaroscopy (FFCD), arterial stiffness by aortal pulse wave velocity
      (aPWV) and flow mediated dilatation (FMD); and effects on metabolic and pro-inflammatory
      markers in circulating blood and urine.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in oral glucose tolerance test (oGGT)</measure>
    <time_frame>Weeks 0, 10, 16 and 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (&gt; 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in finger-fold capillary density by capillaroscopy</measure>
    <time_frame>0, 10, 16 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in aortal pulse wave velocity (aPWV)</measure>
    <time_frame>0, 10, 16 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Aortal pulse wave velocity is measured by a non-invasive oscillometric device.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in flow-mediated dilatation (FMD)</measure>
    <time_frame>0, 10, 16 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed.  Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Glucose Intolerance</condition>
  <condition>Aortic Stiffness</condition>
  <condition>Vasodilation</condition>
  <arm_group>
    <arm_group_label>Glyoxalase 1 inducer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glyoxalase 1 inducers (2), capsule, 90 mg &amp; 120 mg, once daily, 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, capsule, once daily, 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glyoxalase 1 inducer</intervention_name>
    <description>Dietary bioactive</description>
    <arm_group_label>Glyoxalase 1 inducer</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glyoxalase 1 inducer dietary bioactive 1</other_name>
    <other_name>Glyoxalase 1 inducer dietary bioactive 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol, 210 mg</description>
    <arm_group_label>Glyoxalase 1 inducer</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 25 - 40 kg/m2 (&gt;23 kg/m2 for Asians), with normal, impaired fasting or impaired
             postprandial glucose.

          -  No other relevant morbidities.

          -  Women will be preferably post-menopausal.

        Exclusion Criteria:

          -  Severe hypertriglyceridemia.

          -  Uncontrolled hypertension, cardiovascular disease, relevant renal or hepatic disease,
             diabetes, and other relevant morbidity.

          -  Excess alcohol consumption, smoking, acute pharmacological treatment with drugs
             affecting glucose metabolism such as steroids and antibiotics.

          -  Anticoagulants.

          -  Intake of herbal remedies.

          -  Food allergies.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Thornalley, BSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Warwick</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin O Weickert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospitals Coventry &amp; Warwickshire NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheharyar Qureshi, MBBS, MRCP</last_name>
    <phone>07801435928</phone>
    <email>S.A.Qureshi@warwick.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire NHS Trust (UHCW)</name>
      <address>
        <city>Coventry</city>
        <state>Warwickshire</state>
        <zip>CV22DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sheharyar Qureshi, MBBS, MRCP</last_name>
      <phone>07801435928</phone>
      <email>S.A.Qureshi@warwick.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Martin O Weickert, MD</last_name>
      <phone>02476 965971</phone>
      <email>Martin.Weickert@uhcw.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Martin O Weickert, MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheharyar Qureshi, MBBS MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Xue M, Rabbani N, Momiji H, Imbasi P, Anwar MM, Kitteringham N, Park BK, Souma T, Moriguchi T, Yamamoto M, Thornalley PJ. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J. 2012 Apr 1;443(1):213-22. doi: 10.1042/BJ20111648.</citation>
    <PMID>22188542</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warwick</investigator_affiliation>
    <investigator_full_name>Professor Paul J. Thornalley</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Oral glucose tolerance test</keyword>
  <keyword>Flow mediated dilatation</keyword>
  <keyword>Aortal pulse wave velocity</keyword>
  <keyword>Finger-fold capillary density by capillaroscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
